Q4 2024 Madrigal Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Madrigal Pharmaceuticals Inc (MDGL) reported strong financial results with $103 million in net sales for Q4 2024, reflecting a 66% quarter-over-quarter growth.
- The company achieved a significant milestone with the approval of Rezdiffra, the first-ever treatment for MASH, and has been included in updated guidelines by top liver societies in Europe and the US.
- Rezdiffra's launch trajectory is tracking in line with some of the most successful specialty medicine launches in the past decade, indicating strong market demand.
- The company has achieved greater than 80% commercial coverage for Rezdiffra, one quarter ahead of schedule, and continues to expand its prescriber base.
- New two-year data from the MAESTRO-NASH trial shows promising results for Rezdiffra in patients with compensated MASH cirrhosis, supporting its potential benefit in this high-risk population.
- Despite the strong launch, Rezdiffra has penetrated less than 4% of the 315,000 diagnosed patients with F2, F3 MASH, indicating a long road ahead for market expansion.
- The company anticipates an increase in the gross to net discount in 2025, which could impact net sales growth.
- R&D expenses are expected to increase in 2025 compared to 2024, potentially affecting profitability.
- SG&A expenses saw a significant year-over-year increase due to the rapid scale-up of US commercial operations, and further increases are expected in 2025.
- The European launch of Rezdiffra may face challenges due to potential pricing pressures and the need for country-by-country regulatory approvals.
Good day, and thank you for standing by. Welcome to Madrigal Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. (Operator Instructions) As a reminder, today's conference call is being recorded.
I'd like to introduce Ms. Tina Ventura, Chief Investor Relations Officer. Please go ahead.
Thank you, Marvin. Good morning, everyone, and thank you for joining us to discuss Madrigal fourth quarter and full year 2024 earnings. We're also sharing this morning new two-year data from the active treatment open label compensated MASH cirrhosis or F4C arm of the Phase 3, MAESTRO-NASH trial. We issued a press release this morning and have a slide deck that accompanies this webcast, which we'll post on the investor relations section of our website right after the call.
On the call with me today is Bill Sibold, Chief Executive Officer; and Mardi Dier, Chief Financial Officer. They'll provide prepared remarks, and then we'll take your questions. Dr. Michael Charlton, our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
